Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ.

J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

2.

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, Shichita T, Inoue H, Yoshimura A.

Biochem Biophys Res Commun. 2012 Feb 10;418(2):234-40. doi: 10.1016/j.bbrc.2011.12.156. Epub 2012 Jan 9.

PMID:
22252297
3.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142
4.

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y, Crouse K, Dickinson C, Symanowicz P, Hegen M, Banker ME, Vincent F, Unwalla R, Liang S, Gilbert AM, Brown MF, Hayward M, Montgomery J, Yang X, Bauman J, Trujillo JI, Casimiro-Garcia A, Vajdos FF, Leung L, Geoghegan KF, Quazi A, Xuan D, Jones L, Hett E, Wright K, Clark JD, Thorarensen A.

ACS Chem Biol. 2016 Dec 16;11(12):3442-3451. Epub 2016 Nov 10.

PMID:
27791347
5.

Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.

Llop-Guevara A, Porras M, Cendón C, Di Ceglie I, Siracusa F, Madarena F, Rinotas V, Gómez L, van Lent PL, Douni E, Chang HD, Kamradt T, Román J.

Arthritis Res Ther. 2015 Dec 10;17:356. doi: 10.1186/s13075-015-0866-0.

6.

Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.

Stevenson W, Sadrai Z, Hua J, Kodati S, Huang JF, Chauhan SK, Dana R.

Cornea. 2014 Feb;33(2):177-83. doi: 10.1097/ICO.0000000000000019.

PMID:
24342887
7.

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.

Tanaka Y, Yamaoka K.

Mod Rheumatol. 2013 May;23(3):415-24. doi: 10.1007/s10165-012-0799-2. Epub 2012 Dec 5. Review.

PMID:
23212593
8.

Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.

Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, Lubberts E.

Arthritis Rheum. 2010 Apr;62(4):1043-50. doi: 10.1002/art.27336.

9.

Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.

Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N.

J Pharmacol Exp Ther. 2014 Jan;348(1):165-73. doi: 10.1124/jpet.113.209304. Epub 2013 Nov 11.

10.

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.

Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y.

Ann Rheum Dis. 2014 Dec;73(12):2192-8. doi: 10.1136/annrheumdis-2013-203756. Epub 2013 Sep 6.

PMID:
24013646
11.

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.

Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P.

Arthritis Res Ther. 2008;10(1):R14. doi: 10.1186/ar2365. Epub 2008 Jan 30.

12.

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.

Tanaka Y.

J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Epub 2015 Jul 7. Review.

PMID:
26152731
13.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K.

J Immunol. 2010 May 1;184(9):5298-307. doi: 10.4049/jimmunol.0902819. Epub 2010 Apr 2.

14.

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.

Yarilina A, Xu K, Chan C, Ivashkiv LB.

Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.

15.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL.

Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.

16.

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y.

Arthritis Rheum. 2012 Jun;64(6):1790-8. doi: 10.1002/art.34329. Epub 2011 Dec 6.

17.

Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.

Gertel S, Mahagna H, Karmon G, Watad A, Amital H.

Clin Immunol. 2017 Nov;184:77-81. doi: 10.1016/j.clim.2017.04.015. Epub 2017 Apr 28.

PMID:
28461107
18.

CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.

West K.

Curr Opin Investig Drugs. 2009 May;10(5):491-504. Review. Erratum in: Curr Opin Investig Drugs. 2009 Sep;10(9):1004-6. Dosage error in article text.

PMID:
19431082
19.

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.

Elwood F, Witter DJ, Piesvaux J, Kraybill B, Bays N, Alpert C, Goldenblatt P, Qu Y, Ivanovska I, Lee HH, Chiu CS, Tang H, Scott ME, Deshmukh SV, Zielstorff M, Byford A, Chakravarthy K, Dorosh L, Rivkin A, Klappenbach J, Pan BS, Kariv I, Dinsmore C, Slipetz D, Dandliker PJ.

J Pharmacol Exp Ther. 2017 May;361(2):229-244. doi: 10.1124/jpet.116.239723. Epub 2017 Feb 13.

20.

Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo.

Jaen O, Rullé S, Bessis N, Zago A, Boissier MC, Falgarone G.

Immunology. 2009 Jan;126(1):35-44. doi: 10.1111/j.1365-2567.2008.02875.x. Epub 2008 Aug 27.

Supplemental Content

Support Center